Silo Pharma announces initial data from SP-26 study
Silo Pharma (SILO) announced am update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel SP-26 ...
TMCnet1d
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced a positive update ...
Nasdaq1mon
Silo Pharma, Inc. Advances Development of SPC-15 and SP-26 with IND Submission Expected in 2025
Additionally, the company is advancing its ketamine implant, SP-26, for chronic pain treatment, with animal studies set to commence early in 2025. Both SPC-15 and SP-26 may qualify for the FDA’s ...